Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic User Fee Waivers Dropped In Latest House Draft Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

Provision allowing generic drug fee waivers in shortage situations was removed in new House user fee draft, but proposals for a new antibacterial approval pathway and breakthrough designation were not included.


Related Content

GDUFA Facility Fees Should Be Waived Until First ANDA Approved, Petition Argues
Antibiotics Approval Changes GAINing Acceptance; PDUFA May Not Get LPADed Out
Drug Shortage Legislation: Sen. Blumenthal Calls For More Extensive Effort
FDA “Breakthrough” Designation Bill Revives Debate About Legislating Flexibility
Generic User Fee Waivers Created In Draft House Bill, Breaking FDA-Industry Agreement
Conflict Of Interest Rules Get Clean Sweep In House Draft User Fee Bill
PDUFA Draft Bill Would Broaden FDA’s Mission, Make Guidance Development More Public





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts